Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00513682 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 9
- Enrollment target
NCT00513682 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 9 participants.
The verdict
NCT00513682, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a Phase III, multicenter, open-label study, that will evaluate the improvement of nutrient absorption when participants will receive Ultrase® MT20. This study is sponsored by Aptalis (formerly Axcan). This study is performed in children from 7 to 11 years old.
Interventions
- DRUG Ultrase® MT20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00513682
The ClinicalTrials.gov registry entry for NCT00513682 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ultrase® MT20 is the first listed.
NCT00513682 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00513682 about?
NCT00513682 is a clinical study titled "Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)". This is a Phase III, multicenter, open-label study, that will evaluate the improvement of nutrient absorption when participants will receive Ultrase® MT20. This study is sponsored by Aptalis (formerly Axcan). This study is performed in children from 7 to 11 years old.
What is the current status of trial NCT00513682?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 9 participants. The study started on 2007-07. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00513682?
The interventions under investigation include: Ultrase® MT20 (DRUG).
Who is sponsoring clinical trial NCT00513682?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.